Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

50.00
-0.1000-0.20%
Volume:196.04K
Turnover:9.79M
Market Cap:15.29B
PE:22.42
High:50.20
Open:50.20
Low:49.57
Close:50.10
52wk High:55.49
52wk Low:45.77
Shares:305.78M
Float Shares:305.78M
Volume Ratio:0.56
T/O Rate:0.06%
Dividend:2.11
Dividend Rate:4.22%
EPS(TTM):2.23
EPS(LYR):2.47
ROE:7.56%
ROA:2.91%
PB:1.63
PE(LYR):20.28

Loading ...

Celltrion Terminates, Withdraws EMA Trial Application for CT-P51 Biosimilar

MT Newswires Live
·
Jul 14

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

GlobeNewswire
·
Jul 13

Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168

TIPRANKS
·
Jul 13

Emera Keeps Quarterly Dividend at $0.7325 a Share, Payable Aug. 17 to Shareholders of Record on Aug. 3

MT Newswires Live
·
Jul 13

Press Release: Emera Declares Quarterly Dividends

Dow Jones
·
Jul 13

EirGenix Partner Secures EMA Nod for Breast Cancer Biosimilar Vial

MT Newswires Live
·
Jul 13

Biotron Clears First SedRx Milestone After EMA Feedback on Regulatory Pathway

TIPRANKS
·
Jul 13

Top Analyst Reveals Why Citigroup is a Top Bank Stock Ahead of Earnings

Benzinga_recent_news
·
Jul 12

Ethereum Nears Pivotal Price as Wall Street Buying Spree Resumes

Benzinga_recent_news
·
Jul 12

Press Release: Emera Teleconference on August 7 to Discuss Q2 2026 Results

Dow Jones
·
Jul 10

Cosmos Health Expands Share Buyback to 4.14 Million Shares; Continues Open Market Repurchases

GlobeNewswire
·
Jul 10

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

GlobeNewswire
·
Jul 09

Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases

GlobeNewswire
·
Jul 09

Did EMA’s Positive Hopledo Ruling Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative?

Simply Wall St.
·
Jul 08

Cosmos Health Share Buyback Expands to 3.87 Million Shares; Continues Open Market Repurchases

GlobeNewswire
·
Jul 08

Cosmos Health Reports Preliminary Record Q2 and H1 2026 Revenue, Up Over 30% Year-Over-Year; Continues Open Market Share Repurchases

GlobeNewswire
·
Jul 07

Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027

GlobeNewswire
·
Jul 06

Worldcoin price breaks bearish channel with bulls targeting 50-day EMA

cryptonews
·
Jul 03

Veon Launches Digital Finance Push With Mastercard

Benzinga
·
Jul 02

Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM

GlobeNewswire
·
Jul 02